These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32528899)

  • 1. Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes.
    Ochoa S; de Anda-Jáuregui G; Hernández-Lemus E
    Front Oncol; 2020; 10():845. PubMed ID: 32528899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.
    Huang CC; Tu SH; Lien HH; Jeng JY; Liu JS; Huang CS; Wu YY; Liu CY; Lai LC; Chuang EY
    J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S10. PubMed ID: 23046482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis based on DNA methylation and RNA-seq reveals hypermethylation of the up-regulated WT1 gene with potential mechanisms in PAM50 subtypes of breast cancer.
    Ren C; Tang X; Lan H
    PeerJ; 2021; 9():e11377. PubMed ID: 33987034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
    Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
    APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of PCS and PAM50 prostate cancer classification schemes.
    Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification.
    Okimoto LYS; Mendonca-Neto R; Nakamura FG; Nakamura EF; Fenyö D; Silva CT
    BMC Bioinformatics; 2024 Mar; 25(1):92. PubMed ID: 38429657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
    Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
    Front Oncol; 2019; 9():707. PubMed ID: 31448227
    [No Abstract]   [Full Text] [Related]  

  • 11. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer.
    Veerla S; Hohmann L; Nacer DF; Vallon-Christersson J; Staaf J
    NPJ Breast Cancer; 2023 Oct; 9(1):83. PubMed ID: 37857634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
    BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.
    Prat A; Parker JS; Fan C; Perou CM
    Breast Cancer Res Treat; 2012 Aug; 135(1):301-6. PubMed ID: 22752290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular basis of breast cancer pathological phenotypes.
    Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
    J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive function analysis of LMO2 in different breast cancer subtypes.
    Liu Y; Yuan M; Wu C; Zhu T; Sun W
    Oncotarget; 2018 Feb; 9(10):8911-8926. PubMed ID: 29507663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
    Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at
    Madsen MJ; Knight S; Sweeney C; Factor R; Salama M; Stijleman IJ; Rajamanickam V; Welm BE; Arunachalam S; Jones B; Rachamadugu R; Rowe K; Cessna MH; Thomas A; Kushi LH; Caan BJ; Bernard PS; Camp NJ
    Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):644-652. PubMed ID: 29650789
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
    Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
    BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The New Paradigm of Network Medicine to Analyze Breast Cancer Phenotypes.
    Grimaldi AM; Conte F; Pane K; Fiscon G; Mirabelli P; Baselice S; Giannatiempo R; Messina F; Franzese M; Salvatore M; Paci P; Incoronato M
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.